A Comparison Between Severity-Dependent Protocol and Fixed-Dose Regimen of Oral Vitamin D Supplementation on Correction of Hypovitaminosis D Among Dialysis Patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

However, there is no consensus on how best to correct hypovitaminosis D, defined as serum 25-hydroxyvitamin D level <30 ng/mL, in patients with end-stage kidney disease (ESKD).

This study investigated the effect of different vitamin D supplementation regimens on sarcopenia outcomes in dialysis patients.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

This was a prospective randomized controlled trial.

The changes in muscle mass were measured by bioimpedance spectroscopy, muscle strength was assessed by a hand grip dynamometer, physical performance was determined by gait speed, and muscle-related biomarkers were examined.

What Was Measured

The subject headings attached to it are Vitamin D Deficiency, Renal Dialysis, Dietary Supplements, Vitamin D, Kidney Failure, Chronic, Ergocalciferols and Sarcopenia.

The authors tagged it with the keywords muscle mass.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.